Abbott India
Abbott india, keeps proving me wrong. First half – 24 operational revenue growth is 11% ( ajanta H1 sales growth – 8%, Eris – 13%, Mankind – 15%, in that domestic business growth is 11% for mankind) and EPS growth is 28% ( ajanta H1 eps growth – 24%, Eris – flat, Mankind – 39%)
Most astonishing part remains cash flow generation. H1 CFO increased by whooping 83% to 683 Cr from 370 cr H1 last year . 2 years back their yearly CFO was 727 Cr ( for FY 21 )
The reason for lower allocation is inability to understand the leverage business model has. Every year I keep thinking margins and cash flows are peaked but company keeps proving me wrong. Fy24 ROE will be around 35%
| Subscribe To Our Free Newsletter |
